Ciclosporin/Omeprazole - Perle Bioscience

Drug Profile

Ciclosporin/Omeprazole - Perle Bioscience

Alternative Names: Omeprazole/ciclosporin - Perle Biosciences; PRL-001

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Perle Bioscience
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antihyperglycaemics; Ciclosporins; Gastric antisecretories; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Type 1 diabetes mellitus

Most Recent Events

  • 28 Oct 2016 Clinical development is ongoing in Spain (Perle Bioscience pipeline; October 2016)
  • 15 Apr 2016 Perle Bioscience withdraws a clinical trial for Type-1 diabetes mellitus in Spain (EudraCT 2015-000105-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top